U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech

The U.S. Army is facing a significant challenge as its missile stockpile is rapidly depleting, which could take years to replenish. This shortage comes at a time when global tensions are high, highlighting the need for strategic planning in defense resources. Meanwhile, the FDA is considering the approval of a new flu vaccine using mRNA technology, similar to the COVID-19 shots, which could revolutionize how we approach flu prevention. This development is crucial as it promises more effective and quicker vaccine production in the face of future pandemics. Both issues underscore the complex balance between national security and public health innovation.